Decoy Therapeutics Inc.
DCOY· Nasdaq
DCOYDecoy Therapeutics Inc.
Who holds Decoy Therapeutics Inc., from the managers’ Form 13F reports for the quarter ended Jun 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 4K | New | $29K | 0% | Aug 13, 2026 |
| Tower Research Capital LLC (TRC) | 256 | −74.9% | $1.8K | 0% | Aug 11, 2026 |
| UBS Group AG | 25 | −95.4% | $180 | 0% | Aug 13, 2026 |
| Caitong International Asset Management Co., Ltd | 2 | New | $14 | 0% | Aug 5, 2026 |
